Brainstorm Cell Therapeutics (STU:GHD) Total Operating Expense: €7.66 Mil (TTM As of Mar. 2026)


STU:GHD Brainstorm Cell Therapeutics Inc STU:GHD
28 GF Score
Price €2.98
! 3 Warning Signs
View Full Analysis

What is Brainstorm Cell Therapeutics Total Operating Expense?

Brainstorm Cell Therapeutics STU:GHD 28 Total Operating Expense is €7.66 Mil as of Mar. 2026. GuruFocus rates STU:GHD with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Brainstorm Cell Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was €1.77 Mil. Brainstorm Cell Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €7.66 Mil.

Brainstorm Cell Therapeutics Total Operating Expense Related Terms

Brainstorm Cell Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Brainstorm Cell Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brainstorm Cell Therapeutics Total Operating Expense Chart

Brainstorm Cell Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.72 23.43 19.66 11.17 8.50

Brainstorm Cell Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.86 2.23 1.74 1.92 1.77
STU:GHD
28GF Score
Brainstorm Cell Therapeutics Inc STU:GHD
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brainstorm Cell Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €7.66 Mil mean?
Brainstorm Cell Therapeutics (STU:GHD) has a Total Operating Expense of €7.66 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Brainstorm Cell Therapeutics and its competitors.
Is Brainstorm Cell Therapeutics' Total Operating Expense too high?
Brainstorm Cell Therapeutics' current Total Operating Expense is €7.66 Mil. Overall, Brainstorm Cell Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Brainstorm Cell Therapeutics' Total Operating Expense compare to ADAPY and APRE?
Brainstorm Cell Therapeutics' Total Operating Expense of €7.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Brainstorm Cell Therapeutics and its competitors. Brainstorm Cell Therapeutics's current Total Operating Expense is €7.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brainstorm Cell Therapeutics stock overvalued right now?
Brainstorm Cell Therapeutics (STU:GHD) has a current Total Operating Expense of €7.66 Mil. The current Total Operating Expense is €7.66 Mil. Brainstorm Cell Therapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Brainstorm Cell Therapeutics (STU:GHD), the current Total Operating Expense is €7.66 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Brainstorm Cell Therapeutics Business Description

Other Exchanges BCLI:USA
Address 1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company committed to the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases. NurOwn, its proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has one reportable segment specializing in the development and commercialization of autologous cellular therapies for the treatment of ALS.
28GF Score

Get the complete analysis for STU:GHD

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.98
Price